See more : Environmental Impact Acquisition Corp. (ENVIU) Income Statement Analysis – Financial Results
Complete financial analysis of Evotec SE (EVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evotec SE, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- BHP Group Limited (BBL) Income Statement Analysis – Financial Results
- Bionoid Pharma Inc. (BINP) Income Statement Analysis – Financial Results
- Tuscan Holdings Corp. II (THCA) Income Statement Analysis – Financial Results
- Reliance Home Finance Limited (RELHOME.BO) Income Statement Analysis – Financial Results
- Mitsui Mining & Smelting Co., Ltd. (5706.T) Income Statement Analysis – Financial Results
Evotec SE (EVO)
About Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 781.43M | 751.45M | 618.03M | 500.92M | 446.44M | 375.41M | 257.63M | 164.51M | 127.68M | 89.50M | 85.94M | 87.27M | 80.13M | 55.26M | 42.68M | 39.61M | 32.89M | 67.35M | 64.12M | 1.94M | 3.57M | 0.00 | 0.00 |
| Cost of Revenue | 606.38M | 577.38M | 466.49M | 375.18M | 313.55M | 263.39M | 175.06M | 105.95M | 89.69M | 60.12M | 54.72M | 56.24M | 45.14M | 30.92M | 24.26M | 21.98M | 24.86M | 44.40M | 42.99M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 175.05M | 174.07M | 151.54M | 125.74M | 132.89M | 112.02M | 82.57M | 58.55M | 37.99M | 29.38M | 31.22M | 31.02M | 34.99M | 24.35M | 18.42M | 17.64M | 8.02M | 22.95M | 21.13M | 1.94M | 3.57M | 0.00 | 0.00 |
| Gross Profit Ratio | 22.40% | 23.16% | 24.52% | 25.10% | 29.77% | 29.84% | 32.05% | 35.59% | 29.75% | 32.83% | 36.33% | 35.55% | 43.66% | 44.06% | 43.16% | 44.52% | 24.40% | 34.08% | 32.95% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 57.52M | 76.64M | 72.20M | 63.95M | 58.43M | 35.62M | 17.61M | 18.11M | 18.34M | 12.40M | 9.66M | 8.34M | 8.44M | 6.12M | 20.95M | 42.54M | 36.94M | 30.31M | 9.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 152.74M | 142.70M | 96.02M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 16.87M | 13.49M | 9.42M | 9.50M | 9.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 169.61M | 156.19M | 105.45M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 6.10M | 5.27M | 5.02M | 4.27M |
| Other Expenses | -4.57M | -79.62M | -67.78M | -67.21M | -66.60M | 257.00K | -209.00K | 4.00K | 263.00K | 39.00K | 16.00K | 171.00K | 1.49M | 1.80M | -3.29M | -11.87M | 149.00K | 274.00K | 614.00K | -38.30M | -41.99M | -28.93M | -17.01M |
| Operating Expenses | 222.56M | 153.22M | 109.86M | 73.98M | 58.38M | 49.22M | 43.89M | 21.81M | 40.52M | 27.24M | 27.05M | 30.72M | 30.65M | 27.17M | 38.03M | 63.13M | 57.24M | 53.75M | 36.26M | -32.20M | -36.72M | -23.91M | -12.74M |
| Cost & Expenses | 828.93M | 730.60M | 576.36M | 449.16M | 371.92M | 312.61M | 218.96M | 127.76M | 130.21M | 87.35M | 81.77M | 86.96M | 75.79M | 58.08M | 62.30M | 85.11M | 82.10M | 98.15M | 79.25M | -32.20M | -36.72M | -23.91M | -12.74M |
| Interest Income | 9.26M | 8.34M | 2.27M | 1.34M | 2.23M | 898.00K | 903.00K | 863.00K | 533.00K | 469.00K | 261.00K | 655.00K | 413.00K | 241.00K | 499.00K | 2.96M | 1.96M | 1.37M | 851.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.74M | 13.15M | 9.25M | 8.47M | 7.46M | 2.59M | 1.26M | 1.52M | 1.73M | 1.62M | 1.87M | 1.86M | 1.86M | 866.00K | 433.00K | 839.00K | 483.00K | 671.00K | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.98M | 81.66M | 67.61M | 56.06M | 48.81M | 31.29M | 20.77M | 11.89M | 11.94M | 8.54M | 9.17M | 8.82M | 6.61M | 5.51M | 4.78M | 5.13M | 8.94M | 9.61M | 16.40M | 2.14M | 2.03M | 0.00 | 0.00 |
| EBITDA | 24.13M | -86.08M | 298.41M | 75.50M | 86.77M | 105.88M | 35.50M | 45.57M | 24.93M | 5.00M | -14.07M | 4.51M | 13.90M | 9.49M | -39.61M | -70.01M | -36.08M | -22.15M | -18.44M | -67.56M | -31.12M | -23.91M | -12.74M |
| EBITDA Ratio | 3.09% | 12.53% | 15.36% | 19.76% | 27.25% | 25.25% | 22.65% | 29.87% | 7.99% | 12.50% | 15.84% | 11.40% | 17.82% | 16.76% | -40.03% | -125.03% | -109.71% | -29.29% | -0.94% | -1,452.23% | -870.96% | 0.00% | 0.00% |
| Operating Income | -47.51M | 12.50M | 27.32M | 48.52M | 62.59M | 77.46M | 37.50M | 31.34M | 11.64M | -6.38M | -21.35M | -3.20M | 5.21M | 1.72M | -42.30M | -73.21M | -58.12M | -36.76M | -32.97M | -30.26M | -33.15M | -23.91M | -12.74M |
| Operating Income Ratio | -6.08% | 1.66% | 4.42% | 9.69% | 14.02% | 20.63% | 14.55% | 19.05% | 9.12% | -7.13% | -24.84% | -3.67% | 6.50% | 3.10% | -99.10% | -184.81% | -176.72% | -54.58% | -51.42% | -1,562.82% | -927.80% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.09M | -174.81M | 195.98M | -22.72M | -6.03M | -5.46M | -11.16M | 1.61M | 851.00K | 1.22M | -2.30M | -6.55M | 49.00K | 2.15M | -21.16M | -28.20M | 1.37M | -1.46M | -20.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -80.59M | -153.96M | 236.98M | 25.81M | 56.56M | 72.00M | 26.33M | 32.95M | 12.49M | -5.16M | -23.65M | -5.01M | 5.26M | 3.87M | -44.82M | -75.97M | -54.41M | -35.98M | -35.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -10.31% | -20.49% | 38.34% | 5.15% | 12.67% | 19.18% | 10.22% | 20.03% | 9.78% | -5.76% | -27.52% | -5.75% | 6.56% | 7.00% | -105.00% | -191.78% | -165.44% | -53.41% | -55.42% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.32M | 21.70M | 21.47M | 19.56M | 19.33M | -12.06M | 2.33M | 6.11M | -4.03M | 1.82M | 1.79M | -7.49M | -1.40M | 882.00K | 678.00K | 2.32M | -6.35M | 320.00K | -4.53M | -798.91K | 96.08K | 23.90M | 12.77M |
| Net Income | -83.91M | -175.66M | 215.51M | 6.28M | 38.16M | 84.17M | 24.26M | 27.53M | 16.52M | -6.98M | -25.43M | 2.48M | 6.75M | 3.26M | -45.50M | -78.29M | -11.16M | -32.47M | -33.58M | -29.46M | -33.25M | -23.90M | -12.77M |
| Net Income Ratio | -10.74% | -23.38% | 34.87% | 1.25% | 8.55% | 22.42% | 9.42% | 16.73% | 12.94% | -7.80% | -29.59% | 2.84% | 8.42% | 5.90% | -106.59% | -197.63% | -33.92% | -48.21% | -52.38% | -1,521.56% | -930.49% | 0.00% | 0.00% |
| EPS | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.13 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| EPS Diluted | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.12 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| Weighted Avg Shares Out | 176.92M | 176.67M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 131.68M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
| Weighted Avg Shares Out (Dil) | 176.92M | 176.70M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 137.63M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN...
AnalytixInsight Reports First Quarter 2023 Financial Results and MarketWall Strongest Quarter
TORONTO--(BUSINESS WIRE)--Artificial Intelligence company, AnalytixInsight Inc. (“AnalytixInsight”, or the “Company”) (TSX-V: ALY), a financial content and enterprise software solutions provider, reports its financial results for the first quarter ended March 31, 2023, and provides a corporate update including that of...
Intel Makes Technology More Accessible for People with Hearing Loss
SANTA CLARA, Calif.--(BUSINESS WIRE)--Technology is increasingly central to every aspect of human existence. It has the potential to unlock powerful new possibilities, such as helping people hear what they wouldn't be able to hear on their own. More than 1.5...
TurnOnGreen Expands North American EV Charging Network Across Multiple Hotel Properties
MILPITAS, Calif.--(BUSINESS WIRE)--Imperalis Holding Corp. (OTC: IMHC), dba TurnOnGreen, Inc. (“TurnOnGreen” or the “Company”), announced today that it has completed the installation and activation of Electric Vehicle (EV) charging stations at 18 hotels across North America, further expanding the Company's...
TurnOnGreen Completes Municipal Charging Project in Boulder City, Nevada
MILPITAS, Calif.--(BUSINESS WIRE)--Imperalis Holding Corp. (OTC: IMHC), dba TurnOnGreen, Inc. (“TurnOnGreen” or the “Company”), announced today that the city of Boulder City, Nevada, has completed the installation of four public access TurnOnGreen charging stations located at the city Civic Center....
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS...
EVO ICL Sponsors Jonas Brothers’ The Tour
LAKE FOREST, Calif.--(BUSINESS WIRE)--EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome, announced today sponsorship...
STAAR Surgical Reports First Quarter 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Overview Net Sales of $73.5...
ProAmpac offre des solutions d'emballage durable de pointe et un leadership éclairé au salon Interpack 2023
CINCINNATI--(BUSINESS WIRE)--ProAmpac, un leader dans le domaine de l'emballage souple et de la science des matériaux, présentera ses produits à Interpack, le salon international de l'industrie de l'emballage, hall 10, stand D21. L'événement aura lieu à Düsseldorf, en Allemagne, du...
ProAmpac bringt hochmoderne nachhaltige Verpackungslösungen und Vordenkerrolle auf die Interpack 2023
CINCINNATI--(BUSINESS WIRE)--ProAmpac, ein führendes Unternehmen für flexible Verpackungen und Materialwissenschaft, wird seine Produkte auf der Interpack präsentieren, einer weltweiten Messe für die Verpackungsindustrie, in Halle 10, Stand D21. Die Veranstaltung ist für den 4. bis 10. Mai in Düsseldorf, Deutschland,...
Source: https://incomestatements.info
Category: Stock Reports